56 Chapter 3 Epidemiol 2011;32:872e80. 30. Gilpin DF, Small S, Bakshi S, Kearney MP, Cardwell C, Tunney MM. Effcacy of a standard methicillin-resistant Staphylococcus aureus decolonisation protocol in routine clinical practice. J Hosp Infect 2010;75:93e8. 31. Lindgren AK, Nilsson AC, Åkesson P, Gustafsson E, Melander E. Eradication of methicillinresistant Staphylococcus aureus (MRSA) throat carriage: a randomised trial comparing topical treatment with rifampicin-based systemic therapy. Int J Antimicrob Agents 2018;51:642e5. 32. Eum LY, Materniak S, Duffey P, El-Bailey S, Golding GR, Webster D. Randomized controlled trial of chlorhexidine gluconate, intranasal mupirocin, rifampin, and doxycycline versus chlorhexidine gluconate and intranasal mupirocin alone for the eradication of methicillinresistant Staphylococcus aureus (MRSA) colonization. J Assoc Med Microbiol Infect Dis Can 2021;6: 296e306. 33. Wertheim HF, Ammerlaan HS, Bonten MJ, van den Broek PJ, Troelstra A, VandenbrouckeGrauls CM, et al. [Optimisation of the antibiotic policy in The Netherlands. XII. The SWAB guideline for antimicrobial eradication of MRSA in carriers]. Ned Tijdschr Geneeskd 2008;152:2667e71. 34. Larsen AR, Stegger M, Bo€cher S, Sørum M, Monnet DL, Skov RL. Emergence and characterization of community-associated methicillin-resistant Staphyloccocus aureus infections in Denmark, 1999 to 2006. J Clin Microbiol 2009;47:73e8. 35. Humphreys H, Grundmann H, Skov R, Lucet JC, Cauda R. Prevention and control of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2009;15:120e4. 36. Bulanda M, Gruszka M, Heczko B. Effect of mupirocin on nasal carriage of Staphylococcus aureus. J Hosp Infect 1989;14:117e24. 37. Casewell MW, Hill RL. Elimination of nasal carriage of Staphylococcus aureus with mupirocin (‘pseudomonic acid’)da controlled trial. J Antimicrob Chemother 1986;17:365e72. 38. Doebbeling BN, Breneman DL, Neu HC, Aly R, Yangco BG, Holley HP, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993;17:466e74. 39. Soto NE, Vaghjimal A, Stahl-Avicolli A, Protic JR, Lutwick LI, Chapnick EK. Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. Infect Control Hosp Epidemiol 1999;20:351e3. 40. Fernandez C, Gaspar C, Torrellas A, Vindel A, Saez-Nieto JA, Cruzet F, et al. A doubleblind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995;35:399e408. 41. Leigh DA, Joy G. Treatment of familial staphylococcal infectiondcomparison of mupirocin nasal ointment and chlorhexidine/neomycin (Naseptin) cream in eradication of nasal carriage. J Antimicrob Chemother 1993;31:909e17. 42. Martin JN, Perdreau-Remington F, Kartalija M, Pasi OG, Webb M, Gerberding JL, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis 1999;180:896e9. 43. Doebbeling BN, Reagan DR, Pfaller MA, Houston AK, Hollis RJ, Wenzel RP. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994;154:1505e8.
RkJQdWJsaXNoZXIy MTk4NDMw